MXIn Mexico, over 75% of adults suffer from overweight or obesity, a chronic condition linked to more than 200 health complications, including non-alcoholic fatty liver disease (NAFLD). At the International Obesity Congress 2026, the Mexican health authority Cofepris approved two new semaglutide-based treatments: a 7.2 mg dose for obesity management and a 2.4 mg dose for adults with metabolic dysfunction-associated steatotic hepatitis (MASH), an advanced form of NAFLD. Specialists highlighted that obesity is a major risk factor for NAFLD, which can progress to severe complications if untreated. The approval expands therapeutic options for patients needing medical support to achieve significant weight loss and reduce complication risks. Clinical trials showed that adults treated with 7.2 mg semaglutide alongside lifestyle changes lost an average of 21% of their body weight over 72 weeks, with one-third losing at least 25%. The treatment also preserves muscle mass, maintaining mobility and quality of life. The 2.4 mg dose was already available but now has expanded applications.
Bias read (Center): The article presents factual information about the approval of new obesity treatments by a regulatory body, focusing on medical outcomes and expert opinions. It does not take a clear ideological stance, nor does it emphasize political agendas or partisan viewpoints. The framing remains objective, as
